Oligoprogression in Non-Small Cell Lung Cancer
We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing th...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/22/5823 |
| _version_ | 1797510949068865536 |
|---|---|
| author | Daijiro Harada Nagio Takigawa |
| author_facet | Daijiro Harada Nagio Takigawa |
| author_sort | Daijiro Harada |
| collection | DOAJ |
| description | We reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing the same anticancer agents beyond progressive disease after LAT with radiation therapy for OPD are based on the concept of progression in which only a small number of lesions, not more than about four, proliferate after chemotherapy. In the case of OPD harboring driver mutations such as EGFR, prospective studies are underway. However, evidence from retrospective studies support this strategy, which is currently recommended in some guidelines. The prognosis in OPD cases during the administration of an immune checkpoint inhibitor (ICI) is relatively promising. Additionally, LAT with radiation for OPD after the first-line treatment of ICI with cytotoxic chemotherapy may overcome the resistance to the combination drug therapy due to an abscopal effect. To achieve long-term survival in advanced-stage NSCLC, it is important to verify the optimal method and timing of the therapy through prospective comparative studies as well as patient selection based on patient characteristics and biomarker levels. |
| first_indexed | 2024-03-10T05:38:28Z |
| format | Article |
| id | doaj.art-8a9c547006e546d2b1c06ebecb252fe7 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T05:38:28Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8a9c547006e546d2b1c06ebecb252fe72023-11-22T22:43:50ZengMDPI AGCancers2072-66942021-11-011322582310.3390/cancers13225823Oligoprogression in Non-Small Cell Lung CancerDaijiro Harada0Nagio Takigawa1Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama 791-0280, JapanDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama 700-8505, JapanWe reviewed the literature on oligoprogressive disease (OPD) and local ablative therapy (LAT) in patients with advanced non-small cell lung cancer (NSCLC). The frequency of OPD varies depending on its definition and is estimated to be between 15–47%. The implications of the strategy of continuing the same anticancer agents beyond progressive disease after LAT with radiation therapy for OPD are based on the concept of progression in which only a small number of lesions, not more than about four, proliferate after chemotherapy. In the case of OPD harboring driver mutations such as EGFR, prospective studies are underway. However, evidence from retrospective studies support this strategy, which is currently recommended in some guidelines. The prognosis in OPD cases during the administration of an immune checkpoint inhibitor (ICI) is relatively promising. Additionally, LAT with radiation for OPD after the first-line treatment of ICI with cytotoxic chemotherapy may overcome the resistance to the combination drug therapy due to an abscopal effect. To achieve long-term survival in advanced-stage NSCLC, it is important to verify the optimal method and timing of the therapy through prospective comparative studies as well as patient selection based on patient characteristics and biomarker levels.https://www.mdpi.com/2072-6694/13/22/5823non-small cell lung canceroligometastatic diseaseoligoprogressive diseasedriver mutationstyrosine kinase inhibitorimmune checkpoint inhibitor |
| spellingShingle | Daijiro Harada Nagio Takigawa Oligoprogression in Non-Small Cell Lung Cancer Cancers non-small cell lung cancer oligometastatic disease oligoprogressive disease driver mutations tyrosine kinase inhibitor immune checkpoint inhibitor |
| title | Oligoprogression in Non-Small Cell Lung Cancer |
| title_full | Oligoprogression in Non-Small Cell Lung Cancer |
| title_fullStr | Oligoprogression in Non-Small Cell Lung Cancer |
| title_full_unstemmed | Oligoprogression in Non-Small Cell Lung Cancer |
| title_short | Oligoprogression in Non-Small Cell Lung Cancer |
| title_sort | oligoprogression in non small cell lung cancer |
| topic | non-small cell lung cancer oligometastatic disease oligoprogressive disease driver mutations tyrosine kinase inhibitor immune checkpoint inhibitor |
| url | https://www.mdpi.com/2072-6694/13/22/5823 |
| work_keys_str_mv | AT daijiroharada oligoprogressioninnonsmallcelllungcancer AT nagiotakigawa oligoprogressioninnonsmallcelllungcancer |